Akston Launches Clinical Trials for Cancer Therapy in Dogs
Akston, known as the Biotech Built for Pets, has taken a significant step forward in veterinary oncology by launching clinical trials for its novel Ambifect® therapy. This innovative treatment is designed to induce an immune response against PD-L1, a protein on cancer cells, particularly targeting dogs with solid tumors.
Introducing Ambifect®: A Game Changer
The Ambifect® immuno-enhancing therapy stands to alter the landscape of canine cancer treatment dramatically. Its goal is to provide a more accessible approach to advanced veterinary care by minimizing the frequency of treatments and reducing costs. Delivered as an intramuscular injection, this therapy aims to simplify the treatment regimen for both veterinarians and pet parents.
The First Patient: Rocco's Journey
Rocco, an 11-year-old Dutch Shepherd, has become the first participant in this clinical trial at Purdue University. Diagnosed with high-grade soft tissue sarcoma, Rocco's story highlights the urgent need for innovative treatments in veterinary medicine. This trial embodies hope for pet owners facing serious cancer diagnoses for their beloved animals.
Clinical Trial Details and Objectives
Conducted by Dr. Shawna Klahn and Dr. Nikolaos Dervisis at the Purdue Werling Comparative Oncology Research Center, the study will evaluate the safety and tolerability of the Ambifect® therapy in dogs naturally diagnosed with various cancers. The trial will enroll dogs with different solid tumors, including soft tissue sarcoma and melanoma, and aims to gather initial signals of efficacy alongside exploring biomarkers that indicate treatment response.
Advancing Cancer Treatment for Pets
Dr. Todd Zion, co-founder and CEO of Akston, emphasizes the transformative potential of this therapy: "We believe that with our Ambifect® immune-enhancing therapy, we can turn the dog's immune system into a robust anti-cancer defense. Our aim is to lower treatment frequencies while improving accessibility to life-saving care for pets. This clinical trial is a vital step toward bringing advanced immunotherapy to more dogs, all at a fraction of the cost compared to traditional biologics."
Innovation in Cancer Care
Akston's approach utilizes a proprietary Fc-fusion protein platform that promotes the generation of antibodies against disease targets. This unique method not only reduces the necessary dosage and treatment frequency but also aims to expand the reach of cancer immunotherapy to a wider array of pets, including those who may not be able to tolerate conventional treatments.
The Ambifect® therapeutic is a derivative of Akston's lead anti-cPD-L1 monoclonal antibody product, currently under investigation for treating dogs with bladder carcinoma. This dual approach aims to provide comprehensive solutions to combat aggressive cancers prevalent in dogs, and potentially sets the stage for advancements in both canine and human cancer care.
About Akston and Its Mission
Akston is dedicated to improving the health and wellness of pets through pioneering research and development. With a focus on creating targeted treatments that enhance pet care, the company boasts a vertically integrated model and a state-of-the-art GMP biologics facility. This enables the acceleration of innovative products from research to market, ensuring that veterinarians and pet owners have efficient access to cutting-edge therapies.
Frequently Asked Questions
What is Ambifect® therapy?
Ambifect® therapy is a novel immuno-enhancing treatment designed to induce an immune response targeting PD-L1 in dogs suffering from solid tumors.
Who is participating in the clinical trial?
The first patient in the trial is Rocco, an 11-year-old Dutch Shepherd diagnosed with high-grade soft tissue sarcoma.
What are the goals of the clinical trial?
The trial aims to assess the safety, tolerability, efficacy, and explore possible biomarkers for dogs with naturally occurring cancers.
How does Akston's therapy differ from traditional treatments?
Akston's therapy focuses on reducing the frequency and dosage of treatments while enhancing the body's natural immune response to cancer, offering a more accessible solution for pet owners.
What is Akston's mission?
Akston is committed to developing innovative therapies that enhance the efficacy of veterinary treatments while ensuring pet healthcare remains affordable and accessible.
